Zota Health Care: Navigating Growth and Expansion in India's Healthcare Landscape

Zota Health Care Limited, a prominent player in the Indian healthcare sector, has reported a quarter of robust growth and strategic expansion for Q3 FY26. The company, listed on the NSE, continues to solidify its position in providing affordable, high-quality generic medicines, alongside a diverse portfolio of proprietary medicinal, OTC, ayurvedic, cosmetic, and nutraceutical products. Despite a sequential moderation in operating profit and EBITDA, the underlying narrative is one of aggressive investment in network expansion and long-term value creation.

For Q3 FY26, Zota Health Care reported consolidated revenue from operations of INR 142.95 crore, marking a significant year-on-year growth of 98.2% compared to INR 72.12 crore in Q3 FY25. This impressive top-line performance was primarily fueled by the continued scale-up of its Davaindia retail pharmacy network. Consolidated Gross Profit also saw a substantial increase of 113.9% YoY, reaching INR 86.18 crore, up from INR 40.29 crore in the corresponding period last year. This growth was supported by improved scale and operating leverage from higher volumes.

However, the sequential operating profit and EBITDA moderated during the quarter. Consolidated EBITDA stood at INR 1.28 crore, impacted by higher operating expenses. Management attributed this primarily to costs associated with approximately 400+ stores under development or in a non-live stage, where manpower, rentals, and other pre-opening expenses had already commenced. This strategic front-loading of costs is an investment in future growth, expected to normalize as these new stores become fully operational.

Davaindia: The Growth Engine

The Davaindia retail pharmacy chain remains the cornerstone of Zota Health Care's growth strategy, accounting for a dominant 80.3% of the company's Q3 FY26 revenue. The network's expansion has been nothing short of aggressive, with 276 new Davaindia stores added during the quarter (231 Company-Owned Company-Operated or COCO, and 45 Franchisee-Owned Franchisee-Operated or FOFO). This brings the total Davaindia footprint to 2,331 stores as of December 31, 2025, reinforcing its national presence across 23 states and 5 union territories.

The Davaindia model focuses on providing quality generic medicines at substantial discounts, with consumers saving remarkably 30% to 90% compared to branded counterparts. The company's strategic business model is both backward and forward integrated, ensuring control over the entire product life cycle. This approach, combined with a focus on private-label products in medicinal, OTC, and ayurvedic categories, has resonated well with customers, leading to a strong base of 80% repeat customers.

Operational metrics for Davaindia's COCO stores show significant traction. Quarterly footfall increased to 34.31 lakhs in Q3 FY26, up from 15.7 lakhs in Q3 FY25. Quarterly Gross Merchandise Value (GMV) for COCO stores reached INR 79.23 crore, compared to INR 35.07 crore in Q3 FY25. Similarly, FOFO stores reported a GMV of INR 42.49 crore in Q3 FY26, up from INR 31.61 crore in Q3 FY25. The average wallet spend for COCO stores was INR 231, and for FOFO stores, it was INR 299.

Strategic Initiatives and Diversification

Zota Health Care has undertaken several strategic initiatives to bolster its growth and market position. A key milestone was the successful completion of a INR 350 crore Qualified Institutional Placement (QIP). These funds are primarily earmarked to accelerate the rollout of COCO stores under Davaindia, support working capital requirements, and meet general corporate purposes, providing long-term financial flexibility.

To strengthen its internal ecosystem and downstream capabilities, the company approved the incorporation of KMHP Ventures Limited, a new wholly-owned subsidiary with an initial paid-up capital of INR 10 lakh. This entity will focus on the marketing and trading of pharmaceutical products. Additionally, Zota increased its investment in Davaindia Health Mart Limited (DIHML), its wholly-owned subsidiary, through additional equity subscriptions to support COCO store expansion and working capital.

Further expanding its retail generic and specialty pharmacy footprint, Zota acquired a 100% equity stake in Curexis, a retail pharmacy platform operating under the brand 'SKIA'. This acquisition brings a comprehensive portfolio spanning pharmaceuticals, nutraceuticals, cosmetics, ayurvedic, and OTC products, strategically positioning Zota against forecasted competition.

Segmental Performance and Outlook

Beyond Davaindia, other segments also contributed to the overall performance. Domestic Sales generated INR 15.77 crore in Q3 FY26, while Export Sales (SEZ) contributed INR 9.11 crore. The Everyday Herbal Group, where Zota holds a 65.98% stake, reported INR 3.28 crore in revenue for the quarter. This segment is crucial for strengthening Zota's supply chain and expanding its product portfolio, particularly in the high-revenue over-the-counter (OTC) category, which contributed 27% to Q3 FY26 OTC revenue.

Management remains confident in its long-term ambition to cross 5,000 Davaindia stores across India by March 2029. They anticipate employee costs to normalize over the next one to two quarters and foresee gross margins potentially increasing to 70% over the next four to six quarters. The QIP funds are expected to be sufficient for the next two financial years (FY'26-27 and FY'27-28), with future growth increasingly supported by internal accruals as stores mature.

Conclusion

Zota Health Care Limited's Q3 FY26 performance reflects a company in an aggressive growth phase, strategically investing in its Davaindia network and diversifying its product offerings. While expansion-led costs have temporarily impacted sequential profitability, management's clear roadmap, disciplined execution, and focus on unit economics position the company for sustained long-term value creation. The emphasis on affordable, quality-assured generic medicines, coupled with a robust retail engine, underscores Zota's commitment to transforming India's healthcare landscape.